Clinical trials: Motor Vehicle Accident
Yellow Fever, Yellow Fever Immunisation
A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers
This study is a multi-center, double-blind, placebo-controlled, Phase I study to evaluate the safety, reactogenicity, tolerability, and immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) in…
- Trial name
- NCT02743455
- Testing
- ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine
- Where
- 2 sites in United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease, Hemorrhagic Fever
Phase 1 Trial of Ebola Vaccine in Mali
Ebola virus causes an infection known as Ebola virus disease (EVD). This is generally a severe disease which can also lead to death. The 2014 outbreak of EVD in West Africa is the largest ever.
- Trial name
- NCT02267109
- Testing
- Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z
- Where
- Mali
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Influenza
Safety and Immunogenicity of Co-administration of Candidate Influenza Vaccine MVA-NP+M1 and Viroflu® Seasonal Influenza Vaccine
This is a single blinded placebo controlled phase I study, to assess the safety and immunogenicity of co-administration of the candidate influenza vaccine MVA-NP+M1 with the Viroflu® seasonal influenza vaccine.
- Trial name
- NCT02014168
- Testing
- Viroflu® and MVA-NP+M1
- Where
- United Kingdom
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Virus Diseases, Hemorrhagic Fever, Ebola
Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study
This is a Phase 2, open-label, study evaluating the safety and immunogenicity of the 2-dose vaccination regimen, Ad26.ZEBOV, MVA-BN-Filo, in adults and children originally enrolled in the control arm of the EBOVAC-Salone study
- Conditions
- Virus Diseases, Hemorrhagic Fever, Ebola, Infections, Hemorrhagic Fevers, Viral
- Trial name
- NCT05284097
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- Sierra Leone
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Safety, Immunogenicity
EMaBS TB Vaccine Study
The study will commence with a dose-escalation and age de-escalation study in healthy adults and adolescents from the previous Entebbe Mother and Baby Study (EMaBS) in Entebbe, Uganda, focusing on ChAdOx1 85A, to provide safety…
- Trial name
- NCT03681860
- Testing
- ChAdOx185A, MVA85A, BCG
- Where
- 2 sites in Uganda, United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Healthy
A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults
The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.Filo as heterologous prime-boost vaccine regimens in healthy adult participants.
- Trial name
- NCT02860650
- Testing
- Ad26.Filo, MVA-BN-Filo, Ad26.ZEBOV
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Malaria
Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults
This is a single centre, randomized, placebo-controlled phase 1/2 study comparing two malaria vaccine candidates. The first vaccine candidate PfSPZ-CVac (Plasmodium falciparum sporozoites (PfSPZ) challenge administered with a…
- Trial name
- NCT05441410
- Testing
- Pyronaridine Tetraphosphate, Artesunate Drug Combination, PfSPZ Challenge (NF54), MVA ME-TRAP
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Neonate, Maternal Transmission
Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC
This Phase 3 open-label study aims to assess the safety and immune response of the MVA-BN mpox vaccine when administered subcutaneously to pregnant and postpartum women in the Democratic Republic of the Congo (DRC), a population…
- Conditions
- Neonate, Maternal Transmission, Mpox, Vaccination
- Trial name
- PregInPoxVac (NCT06844500)
- Testing
- MVA-BN standard regimen, MVA-BN standard regimen (Administered as PEP)
- Where
- Democratic Republic of the Congo
- Volunteers
- 359 people, healthy volunteers welcome
- Sponsor
- Jean-Pierre Van geertruyden
Smallpox
ACAM 3000 MVA at Harvard Medical School
The purpose of this study is to assess the safety of an experimental smallpox vaccine (MVA: Modified Vaccinia Ankara) and to compare the body's immune (system that fights disease) response to this vaccine.
- Trial name
- NCT00133575
- Testing
- MVA Smallpox Vaccine, Live vaccinia virus vaccine
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Smallpox
Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial
This is a Phase 3 multicenter trial to evaluate safety and immune response of three consecutive production lots of freeze-dried (FD) MVA-BN smallpox vaccine.
- Trial name
- NCT03699124
- Testing
- FD MVA-BN
- Where
- 12 sites in United States
- Volunteers
- 1,129 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Malaria
A Safety and Efficacy Study of ChAdOx1 LS2 and MVA LS2
The purpose of this study is to assess the safety, immunogenicity and efficacy of the candidate malaria vaccines ChAdOx1 LS2 and MVA LS2. Healthy adult volunteers will be recruited and vaccinated in Oxford.
- Trial name
- NCT03203421
- Testing
- ChAdOx1 LS2, MVA LS2
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Ebola Virus Disease
A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z
This is a clinical trial in which healthy volunteers will be administered experimental Ebola vaccines. The investigators will vaccinate four groups of volunteers.
- Trial name
- NCT02451891
- Testing
- MVA-EBO Z, ChAd3-EBO Z
- Where
- United Kingdom
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Healthy
A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants
The purpose of this study is to demonstrate the non-inferiority of a heterologous prime-boost regimen using Ad26.ZEBOV as prime and MVA-BN-Filo as boost administered at different doses at a 56-day interval versus the same regimen…
- Trial name
- NCT02543567
- Testing
- Ad26.ZEBOV 5*10^10 viral particles (vp), Ad26.ZEBOV 2*10^10 (vp), Ad26.ZEBOV 0.8*10^10 (vp)
- Where
- 6 sites in United States
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Healthy
A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants
The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV as heterologous prime-boost vaccine regimens in healthy adult participants.
- Trial name
- NCT02313077
- Testing
- MVA-BN-filo, Ad26. ZEBOV
- Where
- United Kingdom
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Respiratory Syncytial Virus Infections
RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.
A total of 96 subjects will be recruited into 5 groups. Each subject will receive either two vaccinations with MVA-BN-RSV vaccine or placebo.
- Trial name
- NCT02864628
- Testing
- MVA-BN-RSV
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bavarian Nordic
MERS (Middle East Respiratory Syndrome)
Safety, Tolerability and Immunogenicity of Vaccine Candidate MVA-MERS-S
The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a potentially fatal disease with a reported lethality of up to 40% that is under tight epidemiologic control by the World Health Organization (WHO) and currently…
- Trial name
- NCT03615911
- Testing
- vaccine candidate MVA-MERS-S
- Where
- Germany
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Marylyn Addo
Healthy
A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants
The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV as heterologous and homologous prime-boost vaccine regimens in healthy adult participants.
- Trial name
- NCT02325050
- Testing
- MVA-BN-Filo, Ad26. ZEBOV
- Where
- United States
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Ebola Virus Disease, Hemorrhagic Fever
Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO)
Ebola virus causes an infection known as Ebola virus disease (EVD). This it is generally a severe disease which can also lead to death. The 2014 outbreak of EVD in West Africa is the largest ever.
- Trial name
- NCT02368119
- Testing
- VRC-EBOADC069-00-vp, MVA-EbolaZ
- Where
- Mali
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV)…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Trial name
- NCT06059391
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Granulocyte Colony-Stimulating Factor
- Where
- 3 sites in United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Monkeypox
Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC
The goal of this observational study is to monitor and assess the safety profile of the MVA-BN vaccine among staff and study personnel of the PALM-007 study in the Democratic Republic of the Congo.
- Trial name
- NCT05734508
- Testing
- MVA-BN vaccine
- Where
- 3 sites in Democratic Republic of the Congo
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)